Director, MCM Regulatory Policy
Office of Counterterrorism and Emerging Threats, Food and Drug Administration
Liz Sadove has presented at similar sessions at the Preparedness Summit over the years, offering perspectives on FDA's emergency use authorities. She leads a small team of regulatory counsel responsible for advancing and implementing FDA’s statutory, regulatory, and policy framework to support the development and availability of FDA-regulated medical products for public health and national security emergencies. In this capacity, she has helped to refine, shape, interpret and implement FDA's medical countermeasure (MCM) programs, including its Emergency Use Authorization (EUA) program which has been used expansively in response to the COVID-19 pandemic.